Pfiz­er teams up with Sinopharm to mar­ket 12 new drugs in Chi­na — re­port

Pfiz­er and Chi­na-based Sinopharm Group have teamed up to seek ap­proval for 12 new drugs in Chi­na through 2025, Reuters re­port­ed Thurs­day.

Pfiz­er agreed to a strate­gic co­op­er­a­tion agree­ment with the state-owned Sinopharm on Wednes­day, with Sinopharm Pres­i­dent Liu Yong say­ing the agree­ment will ac­cel­er­ate the de­liv­ery of Pfiz­er’s new drugs to pa­tients, Reuters re­port­ed.

The deal builds on Pfiz­er’s re­cent part­ner­ships in Chi­na, with state-owned Mehe­co agree­ing to im­port and dis­trib­ute its Covid-19 an­tivi­ral Paxlovid through next No­vem­ber, as well as an­oth­er 5-year deal with Zhe­jiang Hua­hai signed last Au­gust to pro­duce and sell Paxlovid too.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER